NEW YORK (GenomeWeb News) – Abbott has completed its acquisition of molecular diagnostics firm Ibis Biosciences from Isis Pharmaceuticals for total consideration of $215 million plus earn-out payments.
 
Abbott said last month that it had exercised its option to acquire the remaining 81.4 percent stake of Ibis Biosciences that it didn’t already own for $175 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.